Difference between revisions of "Idarubicin (Idamycin)"
m |
m |
||
| Line 13: | Line 13: | ||
*[http://chemocare.com/bio/idarubicin.asp Idarubicin (Idamycin) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/idarubicin.asp Idarubicin (Idamycin) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/bio/idarubicin.asp Idarubicin (Idamycin) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/idarubicin.asp Idarubicin (Idamycin) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/idarubicin-patient-drug-information Idarubicin (Idamycin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/idarubicin-patient-drug-information Idarubicin (Idamycin) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/idarubicin-patient-drug-information Idarubicin (Idamycin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/idarubicin-patient-drug-information Idarubicin (Idamycin) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | * 9/27/1990: Initial FDA approval | ||
==Also known as== | ==Also known as== | ||
| Line 20: | Line 23: | ||
<references/> | <references/> | ||
| + | [[Category:Drug index]] | ||
| + | [[Category:Chemotherapy]] | ||
| + | [[Category:Vesicant chemotherapy]] | ||
[[Category:Anthracyclines]] | [[Category:Anthracyclines]] | ||
| + | |||
[[Category:Acute myeloid leukemia medications]] | [[Category:Acute myeloid leukemia medications]] | ||
| + | [[Category:Acute promyelocytic leukemia medications]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 1990]] | ||
Revision as of 15:28, 8 November 2014
General information
Class/mechanism: Anthracycline analog of Daunorubicin (Cerubidine), binds and intercalates between DNA base pairs. Inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, resulting in single and double strand DNA breaks. May also inhibit polymerase activity and trigger free radical damage to DNA. In comparison to other anthracyclines, idarubicin lacks a methoxy group at position 4 of the anthracycline structure, which results in it having high lipophilicity and an increased rate of cellular uptake compared with other anthracyclines.[1][2][3][4]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Idarubicin (Idamycin) patient drug information (Chemocare)[5]
- Idarubicin (Idamycin) patient drug information (UpToDate)[6]
History of changes in FDA indication
- 9/27/1990: Initial FDA approval
Also known as
Idamycin, Idamycin PFS, Idaru, idarubicin comp, idarubicin hydrochloride, Ondarubin, Zanedos, Zavedose
References
- ↑ 1.0 1.1 Idarubicin (Idamycin) package insert
- ↑ Idarubicin Preservative-Free Solution (Idamycin PFS) package insert
- ↑ Idarubicin (Idamycin) package insert (locally hosted backup)
- ↑ Idarubicin Preservative-Free Solution (Idamycin PFS) (locally hosted backup)
- ↑ Idarubicin (Idamycin) patient drug information (Chemocare)
- ↑ Idarubicin (Idamycin) patient drug information (UpToDate)